What’s New

Latest News

FDA Approval
FDA Approves Vepdegestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
05/01/2026
Emily Estrada
Based on results from the phase 3 VERITAC-2 trial, the FDA has approved vepdegestrant for patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
Based on results from the phase 3 VERITAC-2 trial, the FDA has approved vepdegestrant for patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
Based on results from the phase...
05/01/2026
Oncology
Oncology
Research Review
Subcutaneous Infliximab Effective Across Ileal and Colonic Crohn’s Disease
05/01/2026
Jessica Garlewicz
Post-hoc analysis shows that endoscopic responses to subcutaneous infliximab were observed across all intestinal segments, including the terminal ileum.
Post-hoc analysis shows that endoscopic responses to subcutaneous infliximab were observed across all intestinal segments, including the terminal ileum.
Post-hoc analysis shows that...
05/01/2026
AIBD NP/PA Institute
AIBD NP/PA Institute
News
Liquid Biopsies Show Promise but Face Key Challenges in Older Adults
04/29/2026
Lisa Kuhns, PhD, MD
Liquid biopsies hold promise for transforming cancer care in older adults—but age-related biological changes may complicate their accuracy and clinical use.
Liquid biopsies hold promise for transforming cancer care in older adults—but age-related biological changes may complicate their accuracy and clinical use.
Liquid biopsies hold promise for...
04/29/2026
Journal of Clinical Pathways
Journal of Clinical Pathways
PharmLaw
Purdue Pharma Sentenced in Federal Opioid Case, Finalizing Fraud and Kickback Conspiracy Resolution
04/29/2026
Grace Taylor, MS, MA
Purdue Pharma’s federal sentencing finalizes a landmark opioid case involving fraud and kickback conspiracies, with lasting compliance implications for the pharmaceutical supply chain.
Purdue Pharma’s federal sentencing finalizes a landmark opioid case involving fraud and kickback conspiracies, with lasting compliance implications for the pharmaceutical supply chain.
Purdue Pharma’s federal...
04/29/2026
Pharmacy Learning Network
Pharmacy Learning Network
News
Glofitamab Emerges as an Accessible, High-Potential Alternative to CAR T Therapy in DLBCL
04/29/2026
Rebecca Amrick
Dr Tycel Phillips from Blood Cancers Today explains how the bispecific antibody glofitamab may offer a more accessible and potentially curative alternative to chimeric antigen receptor (CAR) T-cell therapy for patients with diffuse large...
Dr Tycel Phillips from Blood Cancers Today explains how the bispecific antibody glofitamab may offer a more accessible and potentially curative alternative to chimeric antigen receptor (CAR) T-cell therapy for patients with diffuse large...
Dr Tycel Phillips from Blood...
04/29/2026
First Report Managed Care
First Report Managed Care
News
Health Care Access Linked to Lower PTSD Burden in LGBTQ+ US Military Recruits
04/29/2026
Lisa Kuhns, PhD, MD
Improved health care access may help reduce post-traumatic stress disorder (PTSD) burden among lesbian, gay, bisexual, transgender, and queer (LGBTQ+) military recruits, but bisexual cisgender women remain at higher risk.
Improved health care access may help reduce post-traumatic stress disorder (PTSD) burden among lesbian, gay, bisexual, transgender, and queer (LGBTQ+) military recruits, but bisexual cisgender women remain at higher risk.
Improved health care access may...
04/29/2026
Veterans Health Today
Veterans Health Today
A patient receives psychedelic-assisted therapy
News
Presidential Executive Order Seeks to Expand Psychedelic Access for Tough-To-Treat Mental Illnesses
04/29/2026
Brionna Mendoza
President Donald J. Trump signed an executive order titled “Accelerating Medical Treatments for Serious Mental Illness,” which aims to expand psychedelic therapy access for significant mental health issues, such as suicidality, major...
President Donald J. Trump signed an executive order titled “Accelerating Medical Treatments for Serious Mental Illness,” which aims to expand psychedelic therapy access for significant mental health issues, such as suicidality, major...
President Donald J. Trump signed...
04/29/2026
Psych Congress Network
Psych Congress Network

Latest Research

Vascular Disease Management logo
Vascular Disease Management
Tackling the Calcium Challenge: Managing Recoil, Rupture, and Occlusion
Vol. 23, Issue 4, Issue May 2026
April/May 2026 cover
The Dermatologist
Evolution of Aesthetics in Dermatology
Vol. 34, Issue 3, Issue May 2026

HMP Global Learning Network

Featured Interviews

Advances in Charcot Neuroarthropathy Surgical Techniques Video
Videos
Advances in Charcot Neuroarthropathy Surgical Techniques Video
05/01/2026
Zeeshan S. Husain, DPM, FACFAS, FASPS; Athanasios Garbis, DPM; Kyle Lawton, DPM
In this video, we highlight emerging reconstruction strategies that move beyond traditional rigid fixation toward a more functional approach to limb preservation.
In this video, we highlight emerging reconstruction strategies that move beyond traditional rigid fixation toward a more functional approach to limb preservation.
In this video, we highlight...
05/01/2026
Podiatry Today
Jonathan Friedberg, MD
Videos
Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine in Advanced Hodgkin Lymphoma
04/30/2026
Jonathan W. Friedberg, MD, MMSc
Jonathan Friedberg, MD, MMSc, discusses results from the SWOG S1826 trial which led to the recent FDA approval of nivolumab plus doxorubicin, vinblastine, and dacarbazine for patients with advanced-stage Hodgkin lymphoma.
Jonathan Friedberg, MD, MMSc, discusses results from the SWOG S1826 trial which led to the recent FDA approval of nivolumab plus doxorubicin, vinblastine, and dacarbazine for patients with advanced-stage Hodgkin lymphoma.
Jonathan Friedberg, MD, MMSc,...
04/30/2026
Oncology
Advanced Squamous Cell Carcinoma of the Anal Canal
Videos
Evaluating Retifanlimab for Advanced Squamous Cell Carcinoma of the Anal Canal in the Frontline Setting
03/31/2026
Lingbin Meng, MD, PhD
Lingbin Meng, MD, discusses how adding retifanlimab to chemotherapy may reshape frontline treatment for advanced squamous cell carcinoma of the anal canal.
Lingbin Meng, MD, discusses how adding retifanlimab to chemotherapy may reshape frontline treatment for advanced squamous cell carcinoma of the anal canal.
Lingbin Meng, MD, discusses how...
03/31/2026
First Report Managed Care
Rachid Baz, MD
Videos
BCMA-Targeted Bispecifics and CAR-T in Frontline Multiple Myeloma
03/31/2026
Rachid Baz, MD
Rachid Baz, MD, discusses the emerging role of BCMA-targeted bispecific antibodies and CAR T-cell therapy in transplant-ineligible patients with newly diagnosed multiple myeloma.
Rachid Baz, MD, discusses the emerging role of BCMA-targeted bispecific antibodies and CAR T-cell therapy in transplant-ineligible patients with newly diagnosed multiple myeloma.
Rachid Baz, MD, discusses the...
03/31/2026
Oncology
Julie Carbray, PhD, APRN, PMHNP-BC
Videos
Optimizing ADHD Outcomes With Stimulant and Non-Stimulant Options
03/31/2026
Julie Carbray PhD, PMHNP-BC, PMHCNS-BC, APRN
Psych Congress NP Institute Co-Chair Julie Carbray, PhD, PMHNP-BC, PMHCNS-BC, FAAN, explains key differences in stimulant and non-stimulant treatment options for ADHD.
Psych Congress NP Institute Co-Chair Julie Carbray, PhD, PMHNP-BC, PMHCNS-BC, FAAN, explains key differences in stimulant and non-stimulant treatment options for ADHD.
Psych Congress NP Institute...
03/31/2026
Psych Congress NP Institute
Al B. Benson, III, MD, FACP, FASCO
Videos
First-Line Immunotherapy in Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC): Evidence Review
03/31/2026
Al B. Benson, III, MD, FACP, FASCO
Dr Benson reviews the epidemiology and unmet clinical need in advanced squamous cell carcinoma of the anal canal (SCAC) and examines the evolving role of immunotherapy in the first-line setting. He also contextualizes recent regulatory and...
Dr Benson reviews the epidemiology and unmet clinical need in advanced squamous cell carcinoma of the anal canal (SCAC) and examines the evolving role of immunotherapy in the first-line setting. He also contextualizes recent regulatory and...
Dr Benson reviews the...
03/31/2026
First Report Managed Care
Ira Zackon, MD
Videos
Real-World Analysis Finds Venetoclax-Based Induction Effective for Very Elderly Patients With Acute Myeloid Leukemia
03/02/2026
Ira Zackon, MD
Ira Zackon, MD, shared results from a large real-world analysis which found venetoclax plus a hypomethylating agent is a feasible and effective therapeutic option for patients with AML aged 70 years and older.
Ira Zackon, MD, shared results from a large real-world analysis which found venetoclax plus a hypomethylating agent is a feasible and effective therapeutic option for patients with AML aged 70 years and older.
Ira Zackon, MD, shared results...
03/02/2026
Oncology
Pediatric Video Tutorial: Communicating With Deaf Patients Part 2
Videos
Pediatric Video Tutorial: Communicating With Deaf Patients Part 2
03/02/2026
Scott DeBoer, RN, MSN, CPEN, CEN, CCRN, CFRN
With invaluable insights from a certified interpreter for the deaf, part two of this four-part series rapidly reviews what medical professionals really need to know, and what their deaf patients wish their caregivers knew.
With invaluable insights from a certified interpreter for the deaf, part two of this four-part series rapidly reviews what medical professionals really need to know, and what their deaf patients wish their caregivers knew.
With invaluable insights from a...
03/02/2026
EMSWorld
Allen Kaplan
RESEARCH INSIGHTS
Diagnostic Challenges and Clinical Pitfalls in HAE
03/02/2026
Allen P. Kaplan, MD
Dr Allen Kaplan reviews common diagnostic pitfalls in hereditary angioedema, including misinterpretation of complement testing, confusion with histaminergic angioedema, and challenges in identifying HAE with normal C1 inhibitor.
Dr Allen Kaplan reviews common diagnostic pitfalls in hereditary angioedema, including misinterpretation of complement testing, confusion with histaminergic angioedema, and challenges in identifying HAE with normal C1 inhibitor.
Dr Allen Kaplan reviews common...
03/02/2026
Allergy & Immunology
Zeymer title card
Author Interview
Hospital Outcomes of Patients With Acute Myocardial Infarction-Related Cardiogenic Shock With and Without Revascularization: An Interview With Uwe Zeymer, MD
02/27/2026
Uwe Zeymer, MD
Dr Uwe Zeymer shares background and insights on his article, "Hospital Outcomes of Patients With Acute Myocardial Infarction-Related Cardiogenic Shock With and Without Revascularization."
Dr Uwe Zeymer shares background and insights on his article, "Hospital Outcomes of Patients With Acute Myocardial Infarction-Related Cardiogenic Shock With and Without Revascularization."
Dr Uwe Zeymer shares background...
02/27/2026
Journal of Invasive Cardiology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use